HIV-1 Protease Inhibitor Mutations and Resistance to Maturation Inhibitor Bevirimat
Author Information
Author(s): Fun Axel, van Maarseveen Noortje M, Pokorná Jana, Maas Renée EM, Schipper Pauline J, Konvalinka Jan, Nijhuis Monique
Primary Institution: University Medical Center Utrecht
Hypothesis
Protease inhibitor resistance mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.
Conclusion
The study found that protease inhibitor resistance mutations lead to more diverse resistance profiles for the maturation inhibitor bevirimat.
Supporting Evidence
- The resistance profiles for bevirimat are more diverse for viruses with a mutated protease compared to wild-type.
- Viral replication did not appear to be a major factor during the emergence of bevirimat resistance.
- Mutations selected during in vitro studies included Gag V362I, A364V, S368N, and V370A.
- The protease background affects the development of HIV-1 resistance to bevirimat.
- Bevirimat resistance mutations were more frequently observed in PI resistant but bevirimat naïve HIV-1 isolates.
Takeaway
This study looked at how changes in a virus can make it harder to treat HIV with a new type of medicine called bevirimat. It found that some changes in the virus make it more resistant to this medicine.
Methodology
The study used in vitro selection experiments with ten different viruses containing protease inhibitor resistance mutations to analyze the impact on maturation inhibitor resistance.
Limitations
The study was limited to in vitro experiments and may not fully represent in vivo conditions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website